4-(chloromethyl)thiazol-2-amine hydrochloride | 60090-58-6

• 物质功能分类: 医药中间体
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-(chloromethyl)thiazol-2-amine hydrochloride
• 英文别名: 2-amino-4-chloromethylthiazole hydrochloride；4-(chloromethyl)-1,3-thiazol-2-amine hydrochloride；4‐(chloromethyl)‐1,3‐thiazol‐2‐amine hydrochloride；2-amino-4-chloromethylthiazole monohydrochloride；2-Amino-4-chloromethythiazole, hcl；4-(chloromethyl)-1,3-thiazol-2-amine;hydron;chloride
• CAS: 60090-58-6
• 化学式: C₄H₅ClN₂S*ClH
• mdl: MFCD00035215
• 分子量: 185.077
• InChiKey: NMAKJOWVEDTHOA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.16
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  67.2
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(chloromethyl)thiazol-2-amine hydrochloride 在 氨 作用下， 以 甲醇 为溶剂， 反应 72.0h， 生成 4-(氨基甲基)-1,3-噻唑-2-胺
  参考文献：
  名称：

  Structure–activity relationship studies of antiplasmodial aminomethylthiazoles

  摘要：

  Structure-activity relationship (SAR) studies around a previously reported antimalarial aminomethylthiazole pyrazole carboxamide 1 are reported. Several analogues were synthesised and profiled for in vitro antiplasmodial activity against the drug-sensitive Plasmodium falciparum malaria parasite strain, NF54. Although all the reported analogues exhibited inferior in vitro antiplasmodial activity (IC50 = 0.125-173 mu M) relative to compound 1 (IC50 = 0.0203 mu M), one analogue, compound 5a, retained submicromolar activity (IC50 = 0.125 mu M). (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.09.071
• 作为产物：
  描述：

  硫脲 、 1,3-二氯丙酮 在 乙醇 、 Heptanes 、 正庚烷 作用下， 以 丙酮 为溶剂， 反应 19.0h， 以to afford 4-(chloromethyl)thiazol-2-amine hydrochloride as a white solid (141.3 g, 0.76 mol, 64%)的产率得到4-(chloromethyl)thiazol-2-amine hydrochloride
  参考文献：
  名称：

  Antibacterial Sulfone and Sulfoxide Substituted Heterocyclic Urea Compounds

  摘要：

  本发明提供了一种新型的磺酰基和亚磺酰基取代的杂环脲化合物，具有有用的抗菌活性。本发明还提供了这些化合物作为药物组成物的使用和生产方法。

  公开号：

  US20100286169A1

文献信息

• Thiazole compounds and pharmaceutical composition comprising the same
  申请人：Fujisawa Pharmaceutical Company, Ltd.

  公开号：US04921887A1

  公开（公告）日：1990-05-01

  A thiazole compound of the formula: ##STR1## wherein R.sup.1 is amino or acylamino, R.sup.2 is ar(lower)alkoxy, and A is lower alkylene, and a pharmaceutically acceptable salt thereof, processes for the preparation thereof and pharmaceutical composition comprising the same.

  一种噻唑化合物的化学式为：##STR1## 其中R.sup.1为氨基或酰胺基，R.sup.2为芳基(较低)烷氧基，A为较低烷基，以及其药学上可接受的盐，其制备方法和包含相同化合物的药物组合物。
• [EN] GLUCOKINASE ACTIVATORS AND METHODS OF USING SAME<br/>[FR] ACTIVATEURS DE GLUCOKINASE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2018017910A1

  公开（公告）日：2018-01-25

  A compound, enantiomer, prodrug, diastereomer, or salt is provided which is an activator of the enzyme glucokinase and thus is believed to be useful in treating diabetes and related diseases, which compound has the structure (I). A method for treating diabetes and related disease employing the compound, enantiomer, prodrug, diastereomer, or salt is also provided.

  提供一种化合物、对映体、前药、二对映体或盐，该化合物是葡萄糖激酶的激活剂，因此被认为在治疗糖尿病及相关疾病方面是有用的，该化合物具有结构（I）。还提供了一种利用该化合物、对映体、前药、二对映体或盐治疗糖尿病及相关疾病的方法。
• [EN] SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1<br/>[FR] PYRIDINES SUBSTITUÉES EN TANT QU'INHIBITEURS DE DNMT1
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2017216726A1

  公开（公告）日：2017-12-21

  The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): (Iar) wherein Yar, X1ar, X2ar, R1ar, R2ar, R3ar, R4ar and R5ar are as defined herein; or a pharmaceutically acceptable salt or prodrug thereof. The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and diseases associated with DNMT1 inhibition. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  该发明涉及取代吡啶衍生物。具体而言，该发明涉及符合以下式（Iar）的化合物：（Iar）其中Yar、X1ar、X2ar、R1ar、R2ar、R3ar、R4ar和R5ar如本文所定义；或其药学上可接受的盐或前药。该发明的化合物是DNMT1的选择性抑制剂，可用于治疗癌症、癌前综合征、β血红蛋白病、镰状细胞病、镰状细胞贫血、β地中海贫血以及与DNMT1抑制相关的疾病。因此，该发明进一步涉及包含该发明化合物的药物组合物。该发明还进一步涉及使用该发明化合物或包含该发明化合物的药物组合物抑制DNMT1活性和治疗相关疾病的方法。
• Benzhydrylpiperozinyl thiazole derivatives and pharmaceutical
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US04411900A1

  公开（公告）日：1983-10-25

  Benzhydrylpiperazinyl Thiazole compounds of the formula ##STR1## wherein R.sup.1 is hydrogen, amino, or mono- or di- substituted amino, in which the substituent is selected from lower alkyl, acyl and di(lower)alkylaminomethylene, R.sup.2 is hydrogen, halogen, lower alkyl or aryl, R.sup.3 is ar(lower)alkyl optionally substituted by halogen, A is lower alkylene optionally interrupted by a sulfur atom, and Y is C.sub.1 -C.sub.3 alkylene, having antiallergic activity.

  Benzhydrylpiperazinyl噻唑化合物的化学式为##STR1##其中R.sup.1为氢，氨基，或者单取代或双取代氨基，取代基选自较低的烷基，酰基和二(较低)烷基氨基甲烯，R.sup.2为氢，卤素，较低的烷基或芳基，R.sup.3为可选择地被卤素取代的芳基(较低)烷基，A为可选择地由硫原子中断的较低烷基，Y为C.sub.1 -C.sub.3烷基，具有抗过敏活性。
• [EN] BETA-LACTAMASE INHIBITORS<br/>[FR] INHIBITEURS DE BÊTA-LACTAMASES
  申请人：VENATORX PHARMACEUTICALS INC

  公开号：WO2017044828A1

  公开（公告）日：2017-03-16

  Described herein are compounds and compositions that modulate the activity of beta -lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.

  本发明描述了能够调节β-内酰胺酶活性的化合物和组合物。在某些实施例中，本发明所描述的化合物可抑制β-内酰胺酶。在某些实施例中，本发明所描述的化合物可用于治疗细菌感染。